US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Artiva Biotherapeutics, Inc.

11.31

+0.03000.27%

Post-market: 11.310.00000.00%19:30 EDT

Volume:306.52K

Turnover:3.45M

Market Cap:552.90M

PE:-3.53

High:11.51

Open:11.26

Low:11.05

Close:11.28

52wk High:14.53

52wk Low:2.22

Shares:48.89M

Float Shares:19.90M

Volume Ratio:1.25

T/O Rate:1.54%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2084

EPS(LYR):-3.4309

ROE:-36.58%

ROA:-22.34%

PB:1.59

PE(LYR):-3.30

Loading ...

Overview Company News Filings

Artiva Biotherapeutics Prices $300 Million Shares, Warrants Offering

MT Newswires Live

Artiva Biotherapeutics Posts Positive Early Data for AlloNK Rheumatoid Arthritis Treatment

MT Newswires Live

Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)

Artiva Biotherapeutics prices USD 300 million follow-on equity offering at USD 11.52/share

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS

Artiva Biotherapeutics Inc - Prices Offering of 23.9 Mln Shares at $11.52 per Share and 2.2 Mln Pre-Funded Warrants at $11.5199 per Share

THOMSON REUTERS

BUZZ-Artiva jumps as cell therapy shows benefits in rheumatoid arthritis

Artiva Biotherapeutics Inc - Suspends Offering of Common Stock Under Sales Agreement With Leerink Partners - SEC Filing

THOMSON REUTERS

Artiva Biotherapeutics Q1 EPS $(0.95) Misses $(0.89) Estimate

Benzinga Earnings

Artiva Biotherapeutics Inc - Cash, Cash Equivalents and Investments $86.8 Mln as of March 31, 2026; Funds Operations Into Q2 2027

THOMSON REUTERS

Artiva Biotherapeutics Inc Qtrly EPS $-0.95

THOMSON REUTERS

Press Release: Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva plans Phase 3 rheumatoid arthritis trial of AlloNK plus rituximab in 2026

Artiva Biotherapeutics Inc - Initial Data Shows 71% Acr50 Response in Refractory Ra Patients at Six Months

THOMSON REUTERS

Artiva Announces Positive Initial Clinical Data With Allonk® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

THOMSON REUTERS

Artiva Biotherapeutics Inc - Registrational Trial Initiation Expected in H2 2026, Primary Data in H2 2028

THOMSON REUTERS

Artiva Biotherapeutics Inc - Allonk Shows Favorable Tolerability Profile With No Crs, Icans, or Discontinuations

THOMSON REUTERS

Calendar of U.S. Earnings Expected in the Week Ahead

Artiva Biotherapeutics Inc expected to post a loss of 87 cents a share - Earnings Preview

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Artiva Biotherapeutics, Inc. (ARTV) and Emergent Biosolutions (EBS)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/ARTV/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ARTV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARTV\",,,,,undefined,":{"symbol":"ARTV","market":"US","secType":"STK","nameCN":"Artiva Biotherapeutics, Inc.","latestPrice":11.31,"timestamp":1788379200000,"preClose":11.28,"halted":0,"volume":306518,"hourTrading":{"tag":"盘后","latestPrice":11.31,"preClose":11.31,"latestTime":"19:30 EDT","volume":1458,"amount":16489.98,"timestamp":1788391804721,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0026595744680852074,"floatShares":19899500,"shares":48885777,"eps":-3.20842,"marketStatus":"Not Yet Opened","change":0.03,"latestTime":"09-02 16:00:00 EDT","open":11.26,"high":11.5071,"low":11.05,"amount":3452495.378505,"amplitude":0.040523,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.20842,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788422400000},"marketStatusCode":0,"adr":0,"listingDate":1721361600000,"exchange":"NASDAQ","adjPreClose":11.28,"postHourTrading":{"tag":"盘后","latestPrice":11.31,"preClose":11.31,"latestTime":"19:30 EDT","volume":1458,"amount":16489.98,"timestamp":1788391804721,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.253118,"impliedVol":1.5016,"impliedVolPercentile":0.7419},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ARTV\",,,,,undefined,":{"symbol":"ARTV","floatShares":19899500,"roa":"-22.34%","roe":"-36.58%","lyrEps":-3.430895,"volumeRatio":1.253118,"shares":48885777,"dividePrice":0,"high":11.5071,"amplitude":0.040523,"preClose":11.28,"low":11.05,"week52Low":2.22,"pbRate":"1.59","week52High":14.53,"institutionHeld":0,"latestPrice":11.31,"eps":-3.20842,"divideRate":0,"volume":306518,"delay":0,"ttmEps":-3.20842,"open":11.26,"prevYearClose":4.29,"prevWeekClose":11.09,"prevMonthClose":11.3,"prevQuarterClose":9.7,"fiveDayClose":11.77,"twentyDayClose":11.59,"sixtyDayClose":6.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ARTV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"ARTV","fiscalQuarterEnding":"2026/06","expectedEps":-0.64,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-0.63},{"market":"US","date":"2026-05-08","symbol":"ARTV","fiscalQuarterEnding":"2026/03","expectedEps":-0.88,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":-0.95},{"market":"US","date":"2026-03-10","symbol":"ARTV","fiscalQuarterEnding":"2025/12","expectedEps":-0.87,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"post","actualEps":-0.84},{"market":"US","date":"2025-11-12","symbol":"ARTV","fiscalQuarterEnding":"2025/09","expectedEps":-0.92,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.88},{"market":"US","date":"2025-08-06","symbol":"ARTV","fiscalQuarterEnding":"2025/06","expectedEps":-0.84,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.87}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ARTV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ARTV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":6,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ARTV\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ARTV","date":"2026-09-01","current":-3.5251,"percent":0.16185,"low":-11.820615,"twenty":-5.468753,"median":-1.749489,"eighty":-0.945844,"high":-0.499349,"avg":-3.275906,"sd":2.975718,"marketCap":552458367},"quantilePoints":[{"date":"2024-08-02","current":-10.391793,"twenty":-10.391793,"median":-10.391793,"eighty":-10.391793,"marketCap":269833291},{"date":"2024-08-09","current":-9.862789,"twenty":-10.391793,"median":-10.042112,"eighty":-9.943484,"marketCap":256097171},{"date":"2024-08-16","current":-10.185571,"twenty":-10.248334,"median":-10.131774,"eighty":-9.95245,"marketCap":264478532},{"date":"2024-08-23","current":-8.939273,"twenty":-10.248334,"median":-10.051078,"eighty":-9.342751,"marketCap":232117163},{"date":"2024-08-30","current":-8.088598,"twenty":-10.185571,"median":-9.943484,"eighty":-9.046867,"marketCap":263081639},{"date":"2024-09-06","current":-8.893463,"twenty":-10.142533,"median":-9.800025,"eighty":-8.930111,"marketCap":289259885},{"date":"2024-09-13","current":-8.019798,"twenty":-10.131774,"median":-9.459311,"eighty":-8.763533,"marketCap":260843926},{"date":"2024-09-20","current":-8.759053,"twenty":-10.07439,"median":-9.028935,"eighty":-8.450238,"marketCap":284888199},{"date":"2024-09-27","current":-9.946342,"twenty":-10.07439,"median":-9.323455,"eighty":-8.581333,"marketCap":323504758},{"date":"2024-10-04","current":-11.499524,"twenty":-10.277026,"median":-9.57298,"eighty":-8.727691,"marketCap":374022017},{"date":"2024-10-11","current":-10.566121,"twenty":-10.505561,"median":-9.728296,"eighty":-8.794895,"marketCap":343663087},{"date":"2024-10-18","current":-9.543111,"twenty":-10.587029,"median":-9.800025,"eighty":-8.869568,"marketCap":310389700},{"date":"2024-10-25","current":-7.586699,"twenty":-10.505561,"median":-9.574426,"eighty":-8.581333,"marketCap":246757383},{"date":"2024-10-31","current":-7.579232,"twenty":-10.485041,"median":-9.464706,"eighty":-8.226879,"marketCap":246514511},{"date":"2024-11-08","current":-10.424244,"twenty":-10.485041,"median":-9.3863,"eighty":-8.226879,"marketCap":339048530},{"date":"2024-11-15","current":-4.166082,"twenty":-10.46953,"median":-9.378833,"eighty":-8.149728,"marketCap":255280837},{"date":"2024-11-22","current":-4.310765,"twenty":-10.439178,"median":-9.30416,"eighty":-7.969021,"marketCap":264146442},{"date":"2024-11-29","current":-5.065892,"twenty":-10.411264,"median":-9.046867,"eighty":-7.81669,"marketCap":310417611},{"date":"2024-12-06","current":-4.598149,"twenty":-10.334409,"median":-8.970887,"eighty":-7.365669,"marketCap":281756204},{"date":"2024-12-13","current":-4.233469,"twenty":-10.223229,"median":-8.939273,"eighty":-5.058757,"marketCap":259410023},{"date":"2024-12-20","current":-3.963922,"twenty":-10.173512,"median":-8.885996,"eighty":-4.852633,"marketCap":242893280},{"date":"2024-12-27","current":-4.17401,"twenty":-10.150694,"median":-8.781454,"eighty":-4.667914,"marketCap":255766623},{"date":"2025-01-03","current":-3.95203,"twenty":-10.131774,"median":-8.549971,"eighty":-4.598149,"marketCap":242164600},{"date":"2025-01-10","current":-4.066984,"twenty":-10.131774,"median":-8.396892,"eighty":-4.398368,"marketCap":249208505},{"date":"2025-01-17","current":-2.687539,"twenty":-10.07439,"median":-8.17661,"eighty":-4.337719,"marketCap":164681643},{"date":"2025-01-24","current":-2.477451,"twenty":-10.049285,"median":-8.109405,"eighty":-4.224748,"marketCap":151808300},{"date":"2025-01-31","current":-2.140518,"twenty":-10.011532,"median":-8.012331,"eighty":-4.193829,"marketCap":131162371},{"date":"2025-02-07","current":-1.823404,"twenty":-9.967928,"median":-7.881014,"eighty":-4.108209,"marketCap":111730908},{"date":"2025-02-14","current":-1.589533,"twenty":-9.948785,"median":-7.698708,"eighty":-3.978192,"marketCap":97400205},{"date":"2025-02-21","current":-1.502326,"twenty":-9.945199,"median":-7.508293,"eighty":-3.804572,"marketCap":92056553},{"date":"2025-02-28","current":-1.478543,"twenty":-9.911206,"median":-5.18038,"eighty":-2.77871,"marketCap":90599193},{"date":"2025-03-07","current":-2.0216,"twenty":-9.837683,"median":-5.059946,"eighty":-2.521847,"marketCap":123875572},{"date":"2025-03-14","current":-2.219796,"twenty":-9.795827,"median":-4.998506,"eighty":-2.343471,"marketCap":136020236},{"date":"2025-03-21","current":-1.601424,"twenty":-9.736345,"median":-4.76067,"eighty":-2.165887,"marketCap":98128885},{"date":"2025-03-28","current":-1.319282,"twenty":-9.624289,"median":-4.665536,"eighty":-2.054897,"marketCap":86245441},{"date":"2025-04-04","current":-0.946604,"twenty":-9.574715,"median":-4.606077,"eighty":-1.965312,"marketCap":61882322},{"date":"2025-04-11","current":-0.685729,"twenty":-9.561032,"median":-4.439593,"eighty":-1.797242,"marketCap":44828138},{"date":"2025-04-17","current":-0.857161,"twenty":-9.511749,"median":-4.37617,"eighty":-1.744126,"marketCap":56035173},{"date":"2025-04-25","current":-0.913063,"twenty":-9.383313,"median":-4.344458,"eighty":-1.606181,"marketCap":59689641},{"date":"2025-05-02","current":-0.883248,"twenty":-9.365642,"median":-4.233469,"eighty":-1.560992,"marketCap":57740592},{"date":"2025-05-09","current":-0.740531,"twenty":-9.335033,"median":-4.213649,"eighty":-1.495984,"marketCap":53111599},{"date":"2025-05-16","current":-0.723546,"twenty":-9.26085,"median":-4.193829,"eighty":-1.480232,"marketCap":51893443},{"date":"2025-05-23","current":-0.672592,"twenty":-9.079462,"median":-4.170046,"eighty":-1.376675,"marketCap":48238975},{"date":"2025-05-30","current":-0.696371,"twenty":-9.046867,"median":-4.104641,"eighty":-1.177664,"marketCap":49944393},{"date":"2025-06-06","current":-0.665798,"twenty":-9.028935,"median":-3.995633,"eighty":-0.946604,"marketCap":47751713},{"date":"2025-06-13","current":-0.696371,"twenty":-8.975602,"median":-3.957976,"eighty":-0.913063,"marketCap":49944393},{"date":"2025-06-20","current":-0.570684,"twenty":-8.968058,"median":-3.829149,"eighty":-0.909336,"marketCap":40930039},{"date":"2025-06-27","current":-0.533318,"twenty":-8.961769,"median":-2.822312,"eighty":-0.881757,"marketCap":38250096},{"date":"2025-07-03","current":-0.546906,"twenty":-8.947831,"median":-2.762854,"eighty":-0.830328,"marketCap":39224621},{"date":"2025-07-11","current":-0.60805,"twenty":-8.911787,"median":-2.592405,"eighty":-0.73948,"marketCap":43609983},{"date":"2025-07-18","current":-0.879805,"twenty":-8.888983,"median":-2.477451,"eighty":-0.736237,"marketCap":63100478},{"date":"2025-07-25","current":-1.168544,"twenty":-8.885996,"median":-2.34466,"eighty":-0.73948,"marketCap":83809129},{"date":"2025-08-01","current":-1.019079,"twenty":-8.836712,"median":-2.219796,"eighty":-0.740531,"marketCap":73089357},{"date":"2025-08-08","current":-0.856075,"twenty":-8.776974,"median":-2.136554,"eighty":-0.74119,"marketCap":64318634},{"date":"2025-08-15","current":-0.877783,"twenty":-8.664966,"median":-2.104843,"eighty":-0.766227,"marketCap":65949557},{"date":"2025-08-22","current":-0.90054,"twenty":-8.539516,"median":-2.017636,"eighty":-0.794855,"marketCap":67659360},{"date":"2025-08-29","current":-1.027331,"twenty":-8.461857,"median":-1.938358,"eighty":-0.806285,"marketCap":77185407},{"date":"2025-09-05","current":-1.011075,"twenty":-8.405106,"median":-1.906646,"eighty":-0.809828,"marketCap":75964119},{"date":"2025-09-12","current":-0.864778,"twenty":-8.31765,"median":-1.769891,"eighty":-0.816568,"marketCap":64972526},{"date":"2025-09-19","current":-0.773749,"twenty":-8.226879,"median":-1.740162,"eighty":-0.790778,"marketCap":58133313},{"date":"2025-09-26","current":-0.978565,"twenty":-8.17661,"median":-1.635118,"eighty":-0.805192,"marketCap":73521543},{"date":"2025-10-03","current":-0.959059,"twenty":-8.149728,"median":-1.601424,"eighty":-0.809828,"marketCap":72055997},{"date":"2025-10-10","current":-0.975314,"twenty":-8.101082,"median":-1.571695,"eighty":-0.816568,"marketCap":73277286},{"date":"2025-10-17","current":-0.90054,"twenty":-8.061078,"median":-1.530074,"eighty":-0.825779,"marketCap":67659360},{"date":"2025-10-24","current":-1.573506,"twenty":-8.013824,"median":-1.539983,"eighty":-0.830317,"marketCap":118220688},{"date":"2025-10-31","current":-1.280912,"twenty":-7.969021,"median":-1.537745,"eighty":-0.833281,"marketCap":96237502},{"date":"2025-11-07","current":-1.11836,"twenty":-7.90156,"median":-1.498363,"eighty":-0.837688,"marketCap":84024621},{"date":"2025-11-14","current":-1.102105,"twenty":-7.858868,"median":-1.490435,"eighty":-0.847643,"marketCap":82803333},{"date":"2025-11-21","current":-0.982565,"twenty":-7.819676,"median":-1.476561,"eighty":-0.856509,"marketCap":77807345},{"date":"2025-11-28","current":-1.16544,"twenty":-7.765913,"median":-1.457948,"eighty":-0.858684,"marketCap":92288839},{"date":"2025-12-05","current":-1.170089,"twenty":-7.585206,"median":-1.427209,"eighty":-0.865066,"marketCap":92657012},{"date":"2025-12-12","current":-0.973266,"twenty":-7.550856,"median":-1.356118,"eighty":-0.866579,"marketCap":77070998},{"date":"2025-12-19","current":-1.441302,"twenty":-7.413459,"median":-1.35655,"eighty":-0.869582,"marketCap":114133803},{"date":"2025-12-26","current":-1.332817,"twenty":-7.317879,"median":-1.35655,"eighty":-0.875795,"marketCap":105543087},{"date":"2026-01-02","current":-1.329717,"twenty":-5.60788,"median":-1.355686,"eighty":-0.876285,"marketCap":105297638},{"date":"2026-01-09","current":-1.419605,"twenty":-5.08879,"median":-1.356118,"eighty":-0.877508,"marketCap":112415660},{"date":"2026-01-16","current":-1.38241,"twenty":-5.065892,"median":-1.373111,"eighty":-0.877783,"marketCap":109470271},{"date":"2026-01-23","current":-1.534289,"twenty":-5.058757,"median":-1.38241,"eighty":-0.877783,"marketCap":121497274},{"date":"2026-01-30","current":-1.286323,"twenty":-5.046865,"median":-1.38396,"eighty":-0.878996,"marketCap":101861351},{"date":"2026-02-06","current":-1.199535,"twenty":-5.015947,"median":-1.373111,"eighty":-0.880542,"marketCap":94988778},{"date":"2026-02-13","current":-1.23673,"twenty":-4.922398,"median":-1.361731,"eighty":-0.882362,"marketCap":97934166},{"date":"2026-02-20","current":-1.404107,"twenty":-4.858976,"median":-1.356118,"eighty":-0.88623,"marketCap":111188415},{"date":"2026-02-27","current":-1.689268,"twenty":-4.776526,"median":-1.370012,"eighty":-0.890736,"marketCap":133769726},{"date":"2026-03-06","current":-1.779155,"twenty":-4.679806,"median":-1.38241,"eighty":-0.892087,"marketCap":140887748},{"date":"2026-03-13","current":-1.989358,"twenty":-4.672671,"median":-1.404107,"eighty":-0.894194,"marketCap":166837536},{"date":"2026-03-20","current":-1.626853,"twenty":-4.654437,"median":-1.418531,"eighty":-0.895573,"marketCap":136436029},{"date":"2026-03-27","current":-1.520754,"twenty":-4.628275,"median":-1.425804,"eighty":-0.898589,"marketCap":127538027},{"date":"2026-04-02","current":-1.989358,"twenty":-4.610834,"median":-1.432003,"eighty":-0.90054,"marketCap":166837536},{"date":"2026-04-10","current":-2.004094,"twenty":-4.574366,"median":-1.4506,"eighty":-0.90119,"marketCap":168073369},{"date":"2026-04-17","current":-3.569056,"twenty":-4.471304,"median":-1.457173,"eighty":-0.904441,"marketCap":299318897},{"date":"2026-04-24","current":-3.330333,"twenty":-4.432458,"median":-1.470747,"eighty":-0.907501,"marketCap":279298393},{"date":"2026-05-01","current":-3.01793,"twenty":-4.398368,"median":-1.476546,"eighty":-0.909336,"marketCap":253098721},{"date":"2026-05-08","current":-3.689891,"twenty":-4.369828,"median":-1.481596,"eighty":-0.910081,"marketCap":309452733},{"date":"2026-05-15","current":-3.031745,"twenty":-4.344458,"median":-1.487795,"eighty":-0.913063,"marketCap":263974056},{"date":"2026-05-22","current":-4.458708,"twenty":-4.432458,"median":-1.494399,"eighty":-0.913063,"marketCap":388219702},{"date":"2026-05-29","current":-4.246654,"twenty":-4.403917,"median":-1.50281,"eighty":-0.913063,"marketCap":369756186},{"date":"2026-06-05","current":-4.285717,"twenty":-4.403917,"median":-1.512592,"eighty":-0.913063,"marketCap":373157360},{"date":"2026-06-12","current":-4.464288,"twenty":-4.403917,"median":-1.532182,"eighty":-0.913063,"marketCap":388705584},{"date":"2026-06-18","current":-5.546878,"twenty":-4.459824,"median":-1.539565,"eighty":-0.913448,"marketCap":482966688},{"date":"2026-06-26","current":-4.927458,"twenty":-4.618762,"median":-1.553857,"eighty":-0.916145,"marketCap":429033788},{"date":"2026-07-02","current":-5.468753,"twenty":-4.679014,"median":-1.559086,"eighty":-0.919028,"marketCap":476164340},{"date":"2026-07-10","current":-5.251119,"twenty":-4.852633,"median":-1.578076,"eighty":-0.922185,"marketCap":457214943},{"date":"2026-07-17","current":-5.044646,"twenty":-4.98936,"median":-1.593497,"eighty":-0.929149,"marketCap":439237309},{"date":"2026-07-24","current":-5.652905,"twenty":-5.058757,"median":-1.601424,"eighty":-0.93305,"marketCap":492198445},{"date":"2026-07-31","current":-5.820316,"twenty":-5.116075,"median":-1.607696,"eighty":-0.93435,"marketCap":506774905},{"date":"2026-08-07","current":-6.195168,"twenty":-5.189342,"median":-1.626853,"eighty":-0.936301,"marketCap":562651332},{"date":"2026-08-14","current":-6.082936,"twenty":-5.239958,"median":-1.667148,"eighty":-0.936301,"marketCap":552458367},{"date":"2026-08-21","current":-5.996806,"twenty":-5.366075,"median":-1.692595,"eighty":-0.938902,"marketCap":544635947},{"date":"2026-08-28","current":-6.427457,"twenty":-5.453128,"median":-1.724769,"eighty":-0.944323,"marketCap":583748044},{"date":"2026-09-01","current":-6.082936,"twenty":-5.468753,"median":-1.749489,"eighty":-0.945844,"marketCap":552458367}],"updateTime":1788416246557},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ARTV\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633458539","title":"Artiva Biotherapeutics Prices $300 Million Shares, Warrants Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2633458539","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633458539?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:12","pubTimestamp":1778238768,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics  priced its underwritten offering of about 23.9 million common shares at $11.52 per share and, in lieu of common shares for certain investors, pre-funded warrants to purchase about 2.2 million common shares at $11.52 per share, for a total of approximately $300 million.The company expects to close the offering on or about May 11, according to a Friday statement from Artiva.Shares of Artiva Biotherapeutics were up more than 17% premarket Friday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633430014","title":"Artiva Biotherapeutics Posts Positive Early Data for AlloNK Rheumatoid Arthritis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2633430014","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633430014?lang=en_us&edition=fundamental","pubTime":"2026-05-08 19:06","pubTimestamp":1778238386,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics  said Friday that early clinical data from ongoing AlloNK autoimmune disease trials showed encouraging responses in refractory rheumatoid arthritis patients, supporting a planned Phase 3 registrational study in 2026.The company said 71% of rheumatoid arthritis patients in its Phase 2a trial achieved an ACR50 response at six months, while 19 of 21 patients across two studies showed meaningful reductions in disease activity, with no new biologic or targeted therapies needed after treatment with AlloNK plus rituximab.The US Food and Drug Administration aligned with plans for a single Phase 3 registrational trial comparing AlloNK plus rituximab with rituximab alone in about 150 refractory rheumatoid arthritis patients, the company said.The trial is expected to begin in the second half of 2026, with primary efficacy data anticipated in the second half of 2028.Artiva Biotherapeutics shares were up nearly 20% in premarket activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943048","title":"Artiva Biotherapeutics reports Q1 EPS (95c), consensus (84c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943048","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943048?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:59","pubTimestamp":1778237969,"startTime":"0","endTime":"0","summary":"“Artiva has reached an important inflection point, with positive initial clinical data across multiple autoimmune diseases and FDA alignment on a s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/artiva-biotherapeutics-reports-q1-eps-95c-consensus-84c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/artiva-biotherapeutics-reports-q1-eps-95c-consensus-84c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633437048","title":"Artiva Biotherapeutics prices USD 300 million follow-on equity offering at USD 11.52/share","url":"https://stock-news.laohu8.com/highlight/detail?id=2633437048","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633437048?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:52","pubTimestamp":1778237572,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics priced an underwritten follow-on offering expected to raise about USD 300 million in gross proceeds.Deal consists of 23,871,526 common shares priced at USD 11.52 per share.Offering also includes pre-funded warrants for 2,170,138 common shares priced at USD 11.52, with a USD 0.0001 per-share exercise price.Closing expected around May 11, 2026, subject to customary conditions.Jefferies, TD Cowen, Cantor acting as joint book-running managers.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL1HwPCr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4112","BK4585","SG9999014021.USD","IE00B64PRP62.GBP","LU0314104364.USD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","BK4139","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4588","ARTV","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633437097","title":"Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2633437097","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633437097?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:52","pubTimestamp":1778237552,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUASLNNJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633437020","title":"Artiva Biotherapeutics Inc - Prices Offering of 23.9 Mln Shares at $11.52 per Share and 2.2 Mln Pre-Funded Warrants at $11.5199 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2633437020","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633437020?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:52","pubTimestamp":1778237552,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUASLNNJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633043722","title":"BUZZ-Artiva jumps as cell therapy shows benefits in rheumatoid arthritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2633043722","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633043722?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:48","pubTimestamp":1778237292,"startTime":"0","endTime":"0","summary":"BUZZ-Artiva jumps as cell therapy shows benefits in rheumatoid arthritis** Shares of Artiva Biotherapeutics ARTV.O rises 25% to $14.02 premarket** The biotech firm says its therapy AlloNK targets rheumatoid arthritis, a disease where the immune system attacks joints; 71% saw meaningful improvement at 6 months** No patients relapsed or needed extra immune drugs; therapy was well tolerated with no serious side effects - ARTV** Adds that U.S. FDA backs single late-stage trial comparing AlloNK + rituximab vs rituximab alone in ~150 patients; to start in the second half of 2026** Also shows benefit in Sjgren's  and systemic sclerosis ** Says therapy works by reducing B cells that drive autoimmune disease** As of last close, stock up more than two fold YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL4N41L0VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633437980","title":"Artiva Biotherapeutics Inc - Suspends Offering of Common Stock Under Sales Agreement With Leerink Partners - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2633437980","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633437980?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:40","pubTimestamp":1778236810,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nFWN41L109:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633343205","title":"Artiva Biotherapeutics Q1 EPS $(0.95) Misses $(0.89) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633343205","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633343205?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:33","pubTimestamp":1778236425,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics (NASDAQ:ARTV) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.89) by 6.74 percent. This is a 14.46 percent decrease over losses of $(0.83) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52402823/artiva-biotherapeutics-q1-eps-0-95-misses-0-89-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432779","title":"Artiva Biotherapeutics Inc - Cash, Cash Equivalents and Investments $86.8 Mln as of March 31, 2026; Funds Operations Into Q2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432779?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:31","pubTimestamp":1778236260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA4TJN63:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633343736","title":"Artiva Biotherapeutics Inc Qtrly EPS $-0.95","url":"https://stock-news.laohu8.com/highlight/detail?id=2633343736","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633343736?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:31","pubTimestamp":1778236260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA4TJN63:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633943274","title":"Press Release: Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2633943274","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633943274?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:31","pubTimestamp":1778236260,"startTime":"0","endTime":"0","summary":"Initial AlloNK  clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis  patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents. AlloNK treatment regimen demonstrated a consistent pattern of deep B-cell depletion and tolerability results supportive of outpatient administration in community rheumatology settings. U.S. Food and Drug Administration  alignment on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients, with ACR50 at six months as the primary endpoint; trial initiation planned for H2 2026. Multiple oral and poster presentations at EULAR 2026, including a late-breaking oral presentation on AlloNK clinical efficacy in refractory RA, Sjgren disease  and systemic sclerosis . autoimmune diseases. The broader autoimmune dataset also included 11","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","RA","BK4232","R","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432765","title":"Artiva plans Phase 3 rheumatoid arthritis trial of AlloNK plus rituximab in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432765","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432765?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:30","pubTimestamp":1778236238,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics disclosed initial clinical results for AlloNK with rituximab across several autoimmune diseases, with additional data slated for presentation at EULAR 2026.Early findings in hard-to-treat rheumatoid arthritis showed many patients achieved meaningful symptom relief that held through follow-up, with no need to add new immune-suppressing medicines.Safety profile supported outpatient use, with no severe immune-related toxicities reported and no treatment stoppages tied to adverse events.FDA alignment cleared path for a single Phase 3 registrational trial in refractory rheumatoid arthritis starting in H2 2026, testing AlloNK with rituximab versus rituximab alone in about 150 patients.Company targets primary readout in H2 2028, with a potential biologics license application submission in 2029.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDL8kTJ1B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","SG9999014039.USD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4139","LU2210149790.SGD","BK4585","IE00BN0W2T93.GBP","ARTV","LU2095319765.USD","IE00BN0W2W23.USD","LU0314104364.USD","BK4112","IE00B64PRP62.GBP","NDAQ","IE00BN0W2V16.EUR","LU2210150020.SGD","SG9999014013.SGD","SG9999014021.USD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432248","title":"Artiva Biotherapeutics Inc - Initial Data Shows 71% Acr50 Response in Refractory Ra Patients at Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432248","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432248?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:30","pubTimestamp":1778236200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA32PD84:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633432212","title":"Artiva Announces Positive Initial Clinical Data With Allonk® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2633432212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633432212?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:30","pubTimestamp":1778236200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA32PD84:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633255432","title":"Artiva Biotherapeutics Inc - Registrational Trial Initiation Expected in H2 2026, Primary Data in H2 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2633255432","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633255432?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:30","pubTimestamp":1778236200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA32PD84:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633143224","title":"Artiva Biotherapeutics Inc - Allonk Shows Favorable Tolerability Profile With No Crs, Icans, or Discontinuations","url":"https://stock-news.laohu8.com/highlight/detail?id=2633143224","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633143224?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:30","pubTimestamp":1778236200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nTUA32PD84:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ARTV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633117886","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2633117886","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633117886?lang=en_us&edition=fundamental","pubTime":"2026-05-07 18:00","pubTimestamp":1778148000,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Ares Comm. RE                                   1Q       .07    6:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APYX","AAOI","ASMB","ATHM","AGO","ASC","ASPN","AFRM","AVNT","AKBA","ALGM","AORT","DDOG","BKV","ACLS","ACHR","ARWR","AFCG","AAON","ATLC","AVPT","AMLX","AMPH","ACRE","ABX","APPN","ARGX","AHR","ARW","AMTX","ANAB","ARCT","ASND","AMN","ACMR","ARTV","AMPX","ABSI","BBDC","ABNB","ALTG","BBIO","AURA","ARLO","AKAM","ARHS","ALT","ASTH","ACIW","ALRM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632643956","title":"Artiva Biotherapeutics Inc  expected to post a loss of 87 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632643956","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632643956?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:30","pubTimestamp":1777901423,"startTime":"0","endTime":"0","summary":"Artiva Biotherapeutics Inc  expected to post a loss of87cents a share - Earnings Preview Artiva Biotherapeutics Inc ARTV.OQ ARTV.O is expected to  show no change in quarterly revenue when it reports  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nL8N41H1AW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARTV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632417932","title":"Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Artiva Biotherapeutics, Inc. (ARTV) and Emergent Biosolutions (EBS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632417932","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632417932?lang=en_us&edition=fundamental","pubTime":"2026-05-04 18:30","pubTimestamp":1777890617,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Assembly Biosciences (ASMB), Artiva Biotherapeutics,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-assembly-biosciences-asmb-artiva-biotherapeutics-inc-artv-and-emergent-biosolutions-ebs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-assembly-biosciences-asmb-artiva-biotherapeutics-inc-artv-and-emergent-biosolutions-ebs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EBS","BK4581","BK4583","LABU","LU0029874061.USD","HCSG","XLV","ASMB","BK4585","XBI","ARTV","BK4139","LU0128526141.USD","BK4588","BK4137"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":87,"code":"91000000","status":"200"}]}}